PTC Therapeutics forecasts 2026 product revenue of $700 to $800 million
I'm PortAI, I can summarize articles.
PTC Therapeutics Inc. forecasts 2026 product revenue between $700 to $800 million, reflecting a 19% to 36% growth year-over-year. The company reported 2025 product and royalty revenue of approximately $823 million, surpassing previous guidance, with product revenue around $587.8 million. Anticipated R&D and SG&A expenses for 2026 are projected at $775 million to $815 million, or $680 million to $720 million on a non-GAAP basis. PTC holds a strong cash position of about $1.94 billion as of December 31, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments